Senescent cells as a target for anti-aging interventions: From senolytics to immune therapies.

J Transl Int Med · 2025 · PMC11921816 · PMID 40115034

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

[ 78 ] In another Phase 1 feasibility trial, the safety profile of intermittent D + Q treatment was confirmed in patients of AD ( NCT04063124 ), and there was an overall trend of improvement in SASP and markers of AD pathology.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.